Targeted β2-adrenergic signalling enters human testing with muscle-sparing weight-loss ambitions
Atrogi has begun dosing participants in a human study of ATR-258, an oral, first-in-class modulator designed to bias the β2-adrenergic receptor pathway toward muscle-supportive effects while aiming to limit cardiovascular stimulation. The programme focuses on G protein-coupled receptor (GPCR) signalling biased through G protein-coupled receptor kinase (GRK) targeting at the β2-adrenergic receptor, positioning the candidate for potential use in muscle-sparing approaches to weight management and broader metabolic health, including potential combination with established anti-obesity agents.
Morten Hostrup, Associate Professor at the University of Copenhagen and Principal Investigator of the study, said: “This trial will allow us to rigorously interrogate targeted downstream effector signalling associated with the β2-adrenergic receptor in human skeletal muscle using a highly selective next generation modulator.
“By combining detailed muscle physiological measurements with advanced molecular readouts, we aim to better understand how biased β2-adrenergic signalling regulates muscle growth and function, and how it can potentially be harnessed to preserve, or even augment, muscle function in various conditions of muscle wasting, such as immobilisation, ageing and weight loss.”
Study snapshot: design, dosing and planned readouts
The investigator-initiated study is designed as a mechanistic, hypothesis-testing trial rather than an outcomes study, with a focus on how ATR-258 engages its intended muscle signalling pathways in humans.
| Feature | Details (as disclosed) |
|---|---|
| Candidate | ATR-258 |
| Modality/class | Oral, long-acting β2-agonist; GRK-selective, pathway-biased signalling |
| Objective | Evaluate muscle physiological effects and signalling in human skeletal muscle |
| Design | Investigator-initiated, interventional human study |
| Duration | 8 weeks |
| Population | Overweight male volunteers |
| Dosing | Daily oral dosing of ATR-258 |
| Site leadership | University of Copenhagen |
| Mechanistic focus | GRK-targeted β2-adrenergic signalling with the intent to recapitulate classic β2-agonist muscle effects while limiting cardiovascular effects |
- Planned measurements described for this study include detailed muscle physiology (such as strength and functional performance assessments) and advanced molecular readouts to characterise biased β2-adrenergic signalling in human skeletal muscle.
- The company describes ATR-258 as designed to mimic select exercise-like effects-fat loss, increased muscle and improved metabolism-with potential relevance to muscle-sparing weight loss strategies that seek to separate loss of adipose tissue from loss of lean mass.
Why the muscle question matters for health systems
As health systems grapple with rapid uptake of potent weight-loss medicines and shifting expectations around obesity care, the preservation of muscle is emerging as a critical policy and reimbursement concern.
- Population impact: Ageing demographics and rising obesity increase the prevalence of sarcopenia and frailty, with downstream effects on independence, falls and healthcare utilisation. In many OECD countries, these trends are already influencing long-term care planning and social insurance budgets.
- Clinical context: Rapid or significant weight loss can include a loss of lean tissue; protecting muscle function is a priority when evaluating anti-obesity strategies, particularly in older adults and people with chronic cardiometabolic disease.
- System capacity: Muscle weakness contributes to longer hospital stays, higher rehabilitation needs and readmissions, pressuring workforce and post-acute care resources at a time when many systems face staffing constraints.
- Equity considerations: If effective, an oral therapy could simplify delivery in primary care relative to injectable options, but equitable access will hinge on pricing, coverage and inclusion across age, sex and comorbidity groups in later-phase trials, as well as alignment with national obesity treatment guidelines and benefit-design decisions by payers.
Regulatory oversight and data transparency
Because the trial is being conducted in the European Union, it is governed by the EU Clinical Trials Regulation, which standardises authorisation procedures, ethics review and public information requirements across member states.
- In the European Union, clinical trials require authorisation and ethics approval under this framework, with registration and result reporting via the Clinical Trials Information System (CTIS). This creates a publicly accessible record that health authorities, payers and clinicians can draw on when assessing emerging therapies.
- Investigator-initiated trials are conducted under Good Clinical Practice with safety reporting obligations to competent authorities and ethics committees, even when the primary aim is mechanistic rather than confirmatory.
- For agents acting on β2-adrenergic pathways, typical safety monitoring in early studies includes cardiovascular observations (such as heart rate and blood pressure) and laboratory assessments appropriate to the mechanism of action, reflecting longstanding regulatory caution around off-target stimulation of the heart.
Signals the field will scrutinise
With payers and regulators increasingly focused on the quality-not just the quantity-of weight lost, the study’s readouts will be watched for how convincingly they de-risk muscle outcomes.
- Muscle function and structure: Whether muscle performance measures and molecular signatures align with the targeted biased signalling profile, and whether any gains are clinically meaningful rather than solely biochemical.
- Metabolic markers: Changes consistent with improved metabolic health without compromising lean mass, including parameters that could later be incorporated into endpoints for pivotal trials.
- Cardiovascular tolerability: Incidence and magnitude of class-typical effects, given the longstanding challenges with untargeted β2-agonism and the need to show a differentiated safety profile if ATR-258 is to be positioned for chronic use.
- Generalizability: Results in overweight male volunteers as a foundation for broader populations, including older adults, women and people living with chronic metabolic disease, where regulators and guideline committees will eventually expect representative data.
Study leadership and company outlook
Professor Tore Bengtsson, Chief Scientific Officer and Founder of Atrogi, added: “Professor Hostrup is widely recognised…in the field, and we are excited about his commitment to investigate the muscle signalling effects of ATR-258. We look forward to sharing the results later this year.”
The current work builds on a June 2025 peer‑reviewed study that described a GRK2‑biased approach to muscle-targeted β2‑agonism and reported first‑in‑human safety and tolerability data for ATR-258 in 69 participants, providing the basis for moving into a more detailed exploration of muscle biology.
Paul Little, CEO at Atrogi, commented: “The initiation of this study, and dosing of the first subjects, marks an important milestone for Atrogi. With safety established in phase 1 and a validated mechanism of action, the generation of key muscle physiology data from this trial will underpin ATR-258’s further development across metabolic and muscle-wasting conditions.”
Timeline and near-term milestones
If the current trial confirms the intended signalling bias and an acceptable safety profile, Atrogi is expected to face a series of design and regulatory decisions about how to position ATR-258 within an increasingly crowded metabolic-disease landscape.
- June 2025: Publication reporting GRK2-biased signalling strategy and first‑in‑human safety/tolerability for ATR‑258 (69-subject phase 1).
- 2026: First subjects dosed in an 8‑week, investigator‑initiated human study focusing on muscle physiology.
- 2026 (anticipated): Company leadership indicates results are expected later this year, potentially informing the design of subsequent dose-ranging and combination studies.
